Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio

Journal of Gastrointestinal Surgery

Volumn 12, Issue 8, 2008, Pages 1422-1428

  Smith, Richard A ^a   Ghaneh, Paula ^a   Sutton, Robert ^a   Raraty, Michael ^a   Campbell, Fiona ^a   Neoptolemos, John P ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Ampullary cancer; CA19 9; Prognostic; Resection

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; LYMPHOCYTE; LYMPHOCYTE COUNT; MALE; METHODOLOGY; MIDDLE AGED; PANCREAS DUCT; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; THROMBOCYTE; THROMBOCYTE COUNT;

ADENOCARCINOMA; AGED; BLOOD PLATELETS; CA-19-9 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PLATELET COUNT; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 48849090158     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-008-0554-3     Document Type: Article

References (43)

1. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266-270.
2. Kau SY, Shyr YM, Su CH, Wu CW, Lui WY. Diagnostic and prognostic values of CA19-9 and CEA in periampullary cancers. J Am Coll Surg 1999;188:415-420.
3. Ker CG, Chen JS, Lee KT, Sheen PC, Wu CC. Assessment of serum and bile level of CA19-9 and CA125 in cholangitis and bile duct carcinoma. J Gastroenterol Hepatol 1991;6:505-508.
4. von Ritter C, Eder MI, Stieber P, Lamerz R, Jungst D, Strigl M, Meyer G, Reuter C, Paumgartner G. Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA19-9. Anticancer Res 1997;17:2931-2934.
5. Brockmann J, Emparan C, Hernandez CA, Sulkowski U, Dietl KH, Menzel J, Wolters H, Glodny B, Senninger N. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies. Anticancer Res 2000;20:4941-4947.
6. Itzjowitz S, Kim Y. New carbohydrate tumour markers. Gastroenterology 1986;90:491-494.
7. Schlieman MG, Ho HS, Bold RJ. Utility of tumour markers in determining resectability of pancreatic cancer. Arch Surg 2003;138:951-956.
8. Connor S, Bosonnet L, Alexakis N, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP. Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy. Dig Surg 2005;22:80-85.
9. Halloran CM, Ghaneh P, Connor S, Sutton R, Neoptolemos JP, Raraty MG. Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy. Br J Surg 2008;95:453-459.
10. Sperti C, Pasquali C, Catalini S, Cappellazzo F, Bonadimani B, Behboo R, Pedrazzoli S. CA19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol 1993;52:137-141.
11. Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. Prediction of recurrence and survival by post-resection CA19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 1997;4:551-556.
12. Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998;45:253-259.
13. Lundin J, Roberts PJ, Kuusela P, Roberts PJ. The prognostic value of preoperative serum levels of CA19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994;69:515-519.
14. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez- delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with pancreatic ductal adenocarcinoma. J Clin Oncol 2006;24:2897-2902.
15. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, Imrie CW. Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 2005;92:21-23.
16. Suzuki K, Aiura K, Kitagou M, Hoshimoto S, Takahashi S, Ueda M, Kitajima M. Platelet counts closely correlate with the disease-free survival interval of pancreatic cancer patients. Hepatogastroenterology 2004;51:847-853.
17. Brown KM, Domin C, Aranha GV, Yong S, Shoup M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 2005;189:278-282.
18. Yamaguchi K, Noshiro H, Shimizu S, Morisaki T, Chijiiwa K, Tanaka M. Long-term and short-term survivors after pancreatectomy for pancreatic cancer. Int Surg 2000;85:71-76.
19. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, Pedrazzoli S, Plebani M. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006;32:22-28.
20. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Ghaneh P. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2008; in press.
21. Campbell F, Bennett M, Foulis AJ. Minimum dataset for histopathological reporting of pancreatic, ampulla of Vater and bile duct carcinoma. Royal College of Pathologists; 2002. http://www.rcpath.org.
22. Sobin LH, Wittekind CH. TNM classification of malignant tumours. 5th ed. New York: Wiley, 1997.
23. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using optimal cutpoints in the evaluation of prognostic factors. J Nat Cancer Inst 1994;86:829-835.
24. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2006;165:710-718.
25. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979;5:957-972.
26. McKay CJ, Glen P, McMillan DC. Chronic inflammation and pancreatic cancer. Best Prac Res Clin Gastroent 2008;22:65-73.
27. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002;22:913-922.
28. Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA, Kyriakou DS. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003;26:135-140.
29. Monreal M, Fernandez-Llamazares J, Pinol M, Julian JF, Broggi M, Escola D, Abad A. Platelet count and survival in colorectal cancer-a preliminary study. Thromb Haemost 1998;79:916-918.
30. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002;9:287-291.
31. Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor escape. Cytokine Growth Factor Rev 2007;18:171-182.
32. Romano F, Uggeri F, Crippa S, Di Stefano G, Scotti M, Scaini A, Caprotti R, Uggeri F. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers. J Exp Clin Cancer Res 2004;23:195-200.
33. Beger HG, Treitschke F, Gansauge F, Harada N, Hiki N, Mattfeldt T. Tumor of the ampulla of Vater: Experience with local or radical resection in 171 consecutively treated patients. Arch Surg 1999;134:526-532.
34. Brown KM, Tompkins AJ, Yong S, Aranha GV, Shoup M. Pancreaticoduodenectomy is curative in the majority of patients with node negative ampullary cancer. Arch Surg 2005;140:529-533.
35. Riall TS, Cameron JL, Lillemoe KD, Winter KD, Campbell KA, Hruban RH, Chang D, Yeo CJ. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery 2006;140:764-772.
36. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-782.
37. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T, Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III mulitcenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685-1695.
38. Lee JH, Whittington R, Williams NN, Berry MF, Vaughn DJ, Haller DG, Rosato EF. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 2000;47:945-953.
39. Mehta VK, Fisher GA, Ford JM, Poen JC, Vierra MA, Oberhelman HA, Bastidas AJ. Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater: preliminary report. Arch Surg 2001;136:65-69.
40. Sikora SS, Balachandran P, Dimri K, Rastoqi N, Kumar A, Saxena R, Kapoor VK. Adjuvant chemoradiotherapy in ampullary cancers. Eur J Surg Oncol 2005;31:158-163.
41. Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of Vater. Int J Radiat Oncol Biol Phys 2008;70:735-743.
42. Jagannath P, Dhir V, Shrikhande S, Shah RC, Mulllerpatan P, Mohandas KM. Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy. Br J Surg 2005;92:356-361.
43. Sewnath ME, Karsten TM, Prins MH, Rauws EJ, Obertop H, Gouma DJ. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg 2002;236:17-27.